Côd QR

A real-world retrospective study to assess the effectiveness and safety profile of siponimod in Chinese patients with relapsing forms of multiple sclerosis

Abstract Background Based on its favourable benefit–risk profile in clinical trials, siponimod was approved in China in 2020 for relapsing forms of multiple sclerosis (RMS). We evaluated its real-world (RW) effectiveness and safety profile in patients with RMS in China. Methods This was a retrospect...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Yao Zhang, Hongbo Liu, Zheng Li, Ming Zhou, Min Cai, Lyra Liu, Anne Lin, Yan Xu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMC 2025-11-01
Cyfres:BMC Neurology
Pynciau:
Siponimod
Relapsing forms of multiple sclerosis
Annualised relapse rate
Real-world
Chinese patients
Mynediad Ar-lein:https://doi.org/10.1186/s12883-025-04343-w
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg